Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €22.62 EUR
Change Today -0.243 / -1.06%
Volume 55.7K
As of 3:35 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

carl zeiss meditec ag - br (AFX) Snapshot

Open
€22.92
Previous Close
€22.87
Day High
€23.00
Day Low
€22.62
52 Week High
03/17/15 - €25.78
52 Week Low
12/16/14 - €19.83
Market Cap
1.8B
Average Volume 10 Days
112.3K
EPS TTM
€0.90
Shares Outstanding
81.3M
EX-Date
03/19/15
P/E TM
25.1x
Dividend
€0.40
Dividend Yield
1.77%
Current Stock Chart for CARL ZEISS MEDITEC AG - BR (AFX)

Related News

No related news articles were found.

carl zeiss meditec ag - br (AFX) Related Businessweek News

View More BusinessWeek News

carl zeiss meditec ag - br (AFX) Details

Carl Zeiss Meditec AG operates as a medical technology company worldwide. It provides various products and services in the fields of ophthalmology; neurosurgery; plastic and reconstructive; spine; ear, nose, and throat (ENT); dentistry; gynecology; and oncology. The company’s ophthalmic equipment and systems are used for the diagnosis, progress control, treatment, and follow-up treatment of ophthalmic conditions, such as vision defects (refraction), cataract, glaucoma, and retinal disorders. It also offers laser and diagnostic systems for ophthalmology; ophthalmic implants, including intraocular lenses; and consumables. In addition, the company provides surgical microscopes and visualization solutions for ENT surgeries, or neurosurgery, as well as used to assist with the removal of tumors; and treatment of vascular diseases and functional disorders, as well as provides intraoperative radiation therapy. Carl Zeiss Meditec AG serves physicians in various fields and hospitals through a distribution network of 40 sales companies and 100 agencies. The company was founded in 2002 and is headquartered in Jena, Germany. Carl Zeiss Meditec AG is a subsidiary of Carl Zeiss AG.

2,971 Employees
Last Reported Date: 02/12/15
Founded in 2002

carl zeiss meditec ag - br (AFX) Top Compensated Officers

Chairman of Management Board, Chief Executive...
Total Annual Compensation: €583.5K
Chief Financial Officer and Member of the Man...
Total Annual Compensation: €393.8K
Chief Sales Officer and Member of the Managem...
Total Annual Compensation: €416.5K
Compensation as of Fiscal Year 2014.

carl zeiss meditec ag - br (AFX) Key Developments

Carl Zeiss Meditec AG Announces Preliminary Earnings Results for the First Half of 2015; Provides Earnings Guidance for the First Half of 2015

Carl Zeiss Meditec AG announced preliminary earnings results for the first half of 2015. For the quarter, the company achieved revenue of approximately EUR 498 million. This corresponds to a growth rate against the previous year of approx. 8%. Earnings before interest & taxes (EBIT) amounted to approx. EUR 61 million, a decline of 4% against the previous year. EBIT reached approx. EUR 68 million, which is 5% above the comparable previous year's value. For the first half of 2015, the company’s earnings per share (EPS) are expected at around EUR 0.37. This corresponds to a decline of 24% against the previous year and is mainly related to a negative result from currency hedging.

Carl Zeiss Meditec AG Reports Consolidated Financial Results for the Year 2014; Provides Financial Guidance for Fiscal 2015

Carl Zeiss Meditec AG reported consolidated financial results for the year 2014. The company reported aided by currency effects, revenue rose by 13.6% to EUR 241.1 million against EUR 212.3 million for the last year. In spite of increased R&D spending, earnings before interest and taxes (EBIT) reached EUR 27.9 million in the first quarter compared with EUR 26.5 million for the last year. At EUR 19.4 million, consolidated net income was down by 9.4% compared with EUR 21.4 million for the same period of the previous year. This decline was mainly attributable to a significantly lower result from currency hedging transactions compared with the previous year. In terms of revenue, currency effects once again contributed to growth, accounting for around 3%, in addition to minor acquisition effects; on an adjusted basis, growth would have amounted to 9%. The company is optimistic in the current financial year that it will be able to further strengthen market position. As announced, EBIT margin is also expected to remain within the projected range of 13 to 15% throughout the course of the year 2015.

Carl Zeiss Meditec AG, Q1 2015 Earnings Call, Feb 11, 2015

Carl Zeiss Meditec AG, Q1 2015 Earnings Call, Feb 11, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AFX:GR €22.62 EUR -0.243

AFX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Ellex Medical Lasers Ltd A$0.34 AUD 0.00
IRIDEX Corp $10.02 USD +0.19
LightPath Technologies Inc $0.94 USD -0.0301
Synergetics USA Inc $5.24 USD +0.02
Topcon Corp ¥2,967 JPY +33.00
View Industry Companies
 

Industry Analysis

AFX

Industry Average

Valuation AFX Industry Range
Price/Earnings 22.7x
Price/Sales 1.7x
Price/Book 2.2x
Price/Cash Flow 22.8x
TEV/Sales 1.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CARL ZEISS MEDITEC AG - BR, please visit www.meditec.zeiss.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.